|Bid||117.02 x 1200|
|Ask||118.91 x 900|
|Day's range||115.26 - 118.76|
|52-week range||72.13 - 120.53|
|Beta (5Y monthly)||0.74|
|PE ratio (TTM)||52.35|
|Earnings date||27 May 2021|
|Forward dividend & yield||2.32 (1.96%)|
|Ex-dividend date||21 Dec 2020|
|1y target est||133.54|
These four MedTech stocks -- ABT, JNJ, MDT and MASI -- are expected to gain enormously from FDA's SaMD Action Plan 2021.
Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the first procedures in the investigational device exemption (IDE) pivotal trial to evaluate the PulseSelect™ Pulsed Field Ablation (PFA) System, a novel, breakthrough technology that uses pulsed electric fields to treat atrial fibrillation (AF). The first procedure in the PULSED AF pivotal trial was performed this week at Southcoast Health by Nitesh Sood, M.D., Fall River, Massachusetts; the second procedure was performed by Arnoldas Giedrimas, M.D., also at Southcoast Health. The PULSED AF Trial is the first global, pre-market, multi-center clinical study with IDE approval aimed to establish the safety and efficacy of the PulseSelect System.
Medtronic's (MDT) REVERSE analysis highlights the role played by CRT to slow the progression of HF, thus reinforcing the strong clinical evidence supporting CRT.